Metaraminol: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
 
Line 22: Line 22:
}}
}}
__NOTOC__
__NOTOC__
{{SI}}
{{CMG}}
{{CMG}}


==Overview==
==Overview==
Line 36: Line 32:


==References==
==References==
<div class="references-small"><references/></div>
{{reflist|2}}
 


{{Adrenergic and dopaminergic agents}}
{{Adrenergic and dopaminergic agents}}


[[Category:Sympathomimetic amines]]
[[Category:Sympathomimetic amines]]
[[Category:Drugs]]
[[Category:Amphetamines]]
 
[[Category:Cardiovascular Drugs]]
{{WikiDoc Help Menu}}
[[Category:Drug]]
{{WikiDoc Sources}}

Latest revision as of 00:03, 24 July 2014

Metaraminol
Clinical data
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailabilityn/a
Protein binding~45%
MetabolismHepatic
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC9H13NO2
Molar mass167.205 g/mol

WikiDoc Resources for Metaraminol

Articles

Most recent articles on Metaraminol

Most cited articles on Metaraminol

Review articles on Metaraminol

Articles on Metaraminol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Metaraminol

Images of Metaraminol

Photos of Metaraminol

Podcasts & MP3s on Metaraminol

Videos on Metaraminol

Evidence Based Medicine

Cochrane Collaboration on Metaraminol

Bandolier on Metaraminol

TRIP on Metaraminol

Clinical Trials

Ongoing Trials on Metaraminol at Clinical Trials.gov

Trial results on Metaraminol

Clinical Trials on Metaraminol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Metaraminol

NICE Guidance on Metaraminol

NHS PRODIGY Guidance

FDA on Metaraminol

CDC on Metaraminol

Books

Books on Metaraminol

News

Metaraminol in the news

Be alerted to news on Metaraminol

News trends on Metaraminol

Commentary

Blogs on Metaraminol

Definitions

Definitions of Metaraminol

Patient Resources / Community

Patient resources on Metaraminol

Discussion groups on Metaraminol

Patient Handouts on Metaraminol

Directions to Hospitals Treating Metaraminol

Risk calculators and risk factors for Metaraminol

Healthcare Provider Resources

Symptoms of Metaraminol

Causes & Risk Factors for Metaraminol

Diagnostic studies for Metaraminol

Treatment of Metaraminol

Continuing Medical Education (CME)

CME Programs on Metaraminol

International

Metaraminol en Espanol

Metaraminol en Francais

Business

Metaraminol in the Marketplace

Patents on Metaraminol

Experimental / Informatics

List of terms related to Metaraminol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Metaraminol (INN, trade name Aramine) is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β effect.

Metaraminol is also used in the treatment of priapism. Although not approved for this use, it appears to be effective.[1][2][3]

References

  1. McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. PMID 15703094.
  2. Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. PMID 2258979.
  3. Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.

Template:Adrenergic and dopaminergic agents